StreetInsider.com News Articles

Krystal Biotech (KRYS) PT Raised to $403 at TD Cowen

Thu, 18 Jun 2026 07:48:19 -0400

TD Cowen analyst Ritu Baral raised the price target on Krystal Biotech (NASDAQ: KRYS) to $403.00 (from $306.00) while maintaining a Buy rating.

Krystal Biotech (KRYS) PT Raised to $361 at H.C. Wainwright

Wed, 17 Jun 2026 06:48:47 -0400

H.C. Wainwright analyst Joseph Pantginis raised the price target on Krystal Biotech (NASDAQ: KRYS) to $361.00 (from $310.00) while maintaining a Buy rating.

Form 4 Krystal Biotech, Inc. For: Jun 04 Filed by: Krishnan Suma

Fri, 05 Jun 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260605/26612537.html

Form 4 Krystal Biotech, Inc. For: Jun 04 Filed by: Krishnan Suma

Fri, 05 Jun 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260605/26612537.html

Form 4 Krystal Biotech, Inc. For: Jun 04 Filed by: Krishnan Krish S

Fri, 05 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260605/26612530.html

Form 4 Krystal Biotech, Inc. For: Jun 04 Filed by: Krishnan Krish S

Fri, 05 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260605/26612530.html

Form 144 Krystal Biotech, Inc. Filed by: Krishnan Krish S

Thu, 04 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260604/26606213.html

Form 144 Krystal Biotech, Inc. Filed by: Krishnan Krish S

Thu, 04 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260604/26606213.html

Form 144 Krystal Biotech, Inc. Filed by: Krishnan Suma

Thu, 04 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260604/26606225.html

Form 144 Krystal Biotech, Inc. Filed by: Krishnan Suma

Thu, 04 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260604/26606225.html

Form 4 Krystal Biotech, Inc. For: May 26 Filed by: Thomas John Charles

Wed, 27 May 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26559153.html

Form 4 Krystal Biotech, Inc. For: May 26 Filed by: Thomas John Charles

Wed, 27 May 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260527/26559153.html

Form 144 Krystal Biotech, Inc. Filed by: Thomas John Charles

Tue, 26 May 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26547507.html

Form 144 Krystal Biotech, Inc. Filed by: Thomas John Charles

Tue, 26 May 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260526/26547507.html

Corbus names Nishant Saxena as chief business officer

Thu, 21 May 2026 08:01:06 -0400

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) appointed Nishant Saxena as its first chief business officer, the company announced. Saxena previously served as chief financial officer at Jeune Aesthetics Inc., a subsidiary of Krystal Biotech Inc. (NASDAQ: KRYS).

Saxena brings over 20 years of experience in finance, strategy, capital markets, and corporate development. He spent more than 15 years at Evercore as a managing director in the healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. He holds a bachelor's degree in economics and an MBA from the Wharton School at the University of Pennsylvania.

The appointment comes

Corbus names Nishant Saxena as chief business officer

Thu, 21 May 2026 08:01:06 -0400

The appointment comes

Corbus names Nishant Saxena as chief business officer

Thu, 21 May 2026 08:01:06 -0400

The appointment comes

Corbus names Nishant Saxena as chief business officer

Thu, 21 May 2026 08:01:06 -0400

The appointment comes

Form 8-K Krystal Biotech, Inc. For: May 15

Wed, 20 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260520/26524212.html

Form 8-K Krystal Biotech, Inc. For: May 15

Wed, 20 May 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260520/26524212.html

Krystal Biotech gains UK approval for VYJUVEK gene therapy

Mon, 18 May 2026 08:02:49 -0400

Krystal Biotech Inc. (NASDAQ: KRYS) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency granted marketing authorization for VYJUVEK on May 15 for treating wounds in patients with dystrophic epidermolysis bullosa who have mutations in the COL7A1 gene.

VYJUVEK represents the first genetic medicine approved in the United Kingdom for dystrophic epidermolysis bullosa treatment. The therapy delivers functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing capability.

The UK approval includes flexible administration options allowing for dosing at home or in healthcare settings, with administration possible by patients

Krystal Biotech gains UK approval for VYJUVEK gene therapy

Mon, 18 May 2026 08:02:49 -0400

The UK approval includes flexible administration options allowing for dosing at home or in healthcare settings, with administration possible by patients

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Mon, 18 May 2026 08:00:00 -0400

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan

VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB

PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Mon, 18 May 2026 08:00:00 -0400

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan

VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Mon, 18 May 2026 08:00:00 -0400

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan

VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB